RESPIRATORY-DISTRESS SYNDROME IN PATIENTS WITH ADVANCED CANCER TREATED WITH PENTOXIFYLLINE - A RANDOMIZED STUDY

The inappropriate endogenous secretion of tumour necrosis factor (TNF) could play a role in the pathogenesis of acute respiratory distress s yndrome (ARDS), one of the most frequent causes of death in cancer pat ients. Because of its capacity to inhibit TNF secretion in vitro, pent oxifylline (PTX) could be extremely useful in ARDS therapy. In this st udy 30 advanced cancer patients with ARDS were randomized to receive e ither the conventional care or conventional care plus PTX (100 mg i.v. twice a day for 7 days followed by an oral administration of 400 mg t hree times a day) to evaluate the efficacy of PTX in reducing TNF seru m levels and in improving the symptoms of this syndrome. Serum levels of TNF were measured before and after 7 days of therapy. The percentag e of patients alive at 7 days was significantly higher in the PTX-trea ted group than in the controls (12/15 versus 3/15; P < 0.001). The mea n survival time was significantly higher in the PTX-treated group than in the controls. A clinical and/or radiological improvement was obtai ned in 11/15 patients treated with PTX and in only 2/15 patients in th e conventional care group (P < 0.01). TNF mean levels significantly de crease in the PTX-treated group. These data confirm in vivo the capaci ty of PTX to inhibit TNF secretion in patients with ARDS. Moreover PTX therapy may improve the symptoms related to ARDS without particular t oxic effects.